Top Markets
#1 MowCat MowCat +49.07%
#2 Velvet Velvet +36.37%
#3 Derive Derive +21.24%
#4 Quack AI Quack AI +19.75%
#5 Audiera Audiera +19.69%
#6 MarsCoin MarsCoin +16.65%
#7 Bermuda Shorts Bermuda Shorts +16.51%
#8 aPriori aPriori +15.29%
#9 Biconomy Biconomy +13.82%
#10 Geodnet Geodnet +12.49%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
Rank in Stocks #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Share Price
$2.37
Last synced: 2025-12-15
Market Cap
$3.99M
Change (1 day)
-5.58%
Change (1 year)
24.74%
Country
US
Trade Qualigen Therapeutics, Inc. (QLGN)

Category

Healthcare
P/B ratio for Qualigen Therapeutics, Inc. (QLGN)
P/B ratio as of 2026 TTM: 0
According to Qualigen Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Qualigen Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE